Research Peptide Overview

Retatrutide is an investigational peptide studied for its role as a triple hormone receptor agonist, targeting:

• GLP-1
• GIP
• Glucagon receptors

Retatrutide is not FDA-approved for general clinical use and is intended for research purposes only.

Potential Benefits & Uses

Advanced Weight Management Support

Significant reductions in body weight
Decreased appetite and caloric intake
Improved metabolic efficiency

Its triple-pathway activity may produce stronger effects than GLP-1-only therapies.

Appetite & Satiety Regulation

By acting on incretin and glucagon pathways.

Retatrutide may help:

Enhance feelings of fullness
Reduce cravings
Support portion control

Metabolic & Cardiometabolic Research

Ongoing studies are exploring Retatrutide’s impact on:

Insulin sensitivity
Lipid metabolism
Energy expenditure
Obesity-related metabolic markers

Potential Side Effects & Safety Notes

Retatrutide may cause side effects similar to GLP-1-based therapies, including:

Nausea
Vomiting
Diarrhea or constipation
Decreased appetite
Fatigue
Abdominal discomfort

⚠️ Long-term safety is still being evaluated in clinical trials.

Prefilled Syringe Format

Retatrutide is supplied as four prefilled insulin syringes, prepared and ready for injection. Each syringe contains a measured weekly amount for convenience and consistent handling.

❄ Storage & Shipping:
Prefilled syringes are shipped cold to maintain integrity and should be stored refrigerated upon arrival.

Retatrutide is not FDA-approved, informational purposes only.

Great things are on the horizon